All In Biotech

Drug Trial Radar · NCT00057811

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy

Last checked: Nov 20, 2026Latest source record: Sep 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

97

Actual

Start

Jun 2004

Primary completion

Oct 2009

Study completion Jul 2014

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Apr 9, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.

Conditions

  • Childhood Burkitt Lymphoma
  • Childhood Diffuse Large Cell Lymphoma
  • Childhood Immunoblastic Large Cell Lymphoma
  • Stage I Childhood Large Cell Lymphoma
  • Stage I Childhood Small Noncleaved Cell Lymphoma
  • Stage II Childhood Large Cell Lymphoma
  • Stage II Childhood Small Noncleaved Cell Lymphoma
  • Stage III Childhood Large Cell Lymphoma
  • Stage III Childhood Small Noncleaved Cell Lymphoma
  • Stage IV Childhood Large Cell Lymphoma
  • Stage IV Childhood Small Noncleaved Cell Lymphoma
  • Untreated Childhood Acute Lymphoblastic Leukemia

Interventions

  • doxorubicin hydrochlorideDrug

    Given IV, IT, or orally

  • cyclophosphamideDrug

    Given IV

  • methotrexateDrug

    Given IV or IT

  • rasburicaseDrug

    Given IV

  • leucovorin calciumDrug

    Given IV or orally

  • prednisoneDrug

    Given IV or orally

  • methylprednisoloneDrug

    Given IV or orally

  • filgrastimBiological

    Given subcutaneously

  • rituximabBiological

    Given IV

  • cytarabineDrug

    Given IT

  • etoposideDrug

    Given IV

  • vincristine sulfateDrug

    Given IV

  • hydrocortisone sodium succinateDrug

    Given IT

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Grade ≥ 3 StomatitisTime frame: Up to 1 year
  2. Response RateTime frame: Up to 5 years
  3. Minimal Residual DiseaseTime frame: Not Provided
  4. Toxic DeathTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Oncology Group

    Arcadia, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.